Knowledge Hub

Global Genital Herpes Market By Analysis, Shares, Forecast To 2017

Press Release   •   Aug 30, 2017 06:22 EDT

About  Genital Herpes Market

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get Sample copy of this Report @

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 17 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Genital Herpes - Overview 6

Genital Herpes - Therapeutics Development 7

Pipeline Overview 7

View Sample PDF @

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Genital Herpes - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Genital Herpes - Companies Involved in Therapeutics Development 23

Abivax SA 23

Admedus Ltd 23

AiCuris GmbH & Co KG 24

Biomere LLC 24

Foamix Pharmaceuticals Ltd 25

Genocea Biosciences Inc 25

GenVec Inc 26

Immune Design Corp 26

JN-International Medical Corp 27

NanoBio Corp 27

NanoViricides Inc 28

Profectus BioSciences Inc 28

Redbiotec AG 29

Sanofi Pasteur SA 29

Starpharma Holdings Ltd 30

Vaccibody AS 30

Vical Inc 31

Genital Herpes - Drug Profiles 32

ABX-196 - Drug Profile 32

acyclovir - Drug Profile 33

Aspidasept - Drug Profile 34

astodrimer - Drug Profile 35

G-103 - Drug Profile 40

GEN-003 - Drug Profile 41

genital herpes (virus like particle) vaccine - Drug Profile 47

genital herpes vaccine - Drug Profile 48

genital herpes vaccine - Drug Profile 51

genital herpes vaccine - Drug Profile 52

genital herpes vaccine - Drug Profile 53

genital herpes vaccine - Drug Profile 54

GV-2207 - Drug Profile 55

herpes simplex virus [type 1, 2] vaccine - Drug Profile 56

herpes simplex virus 2 vaccine - Drug Profile 57

herpes simplex virus 2 vaccine - Drug Profile 58

herpes simplex virus 2 vaccine - Drug Profile 59

herpes simplex virus 2 vaccine - Drug Profile 61

herpes simplex virus 2 vaccine - Drug Profile 62

HSV-529 - Drug Profile 63

NN-001 - Drug Profile 65

pritelivir - Drug Profile 66

Profavax HSV-1 - Drug Profile 69

Profavax HSV-2 - Drug Profile 70

Small Molecule for Genital Herpes - Drug Profile 71

Theravax HSV-1 - Drug Profile 72

Theravax HSV-2 - Drug Profile 73

VCLHB-01 - Drug Profile 74

VCLHM-01 - Drug Profile 76

VMTX-004 - Drug Profile 78

Genital Herpes - Dormant Projects 79

Genital Herpes - Discontinued Products 81

Genital Herpes - Product Development Milestones 82

Featured News & Press Releases 82

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

Send An Enquiry Request @

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074